RAVULIZUMAB
ravulizumab 300 mg/3 mL injection, 3 mL vial
RAVULIZUMAB (13791W)
13791W
Manner of administration:Injection
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Initial treatment - Initial (new patient) loading dose
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Switch from PBS-subsidised eculizumab (all phases) - loading dose
Restriction
Indication: Atypical haemolytic uraemic syndrome (aHUS)
Treatment phase: Recommencement of treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $6,623.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ultomiris | |||||